• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

近期的 p53-MDM2 蛋白-蛋白相互作用小分子抑制剂。

Recent Small-Molecule Inhibitors of the p53-MDM2 Protein-Protein Interaction.

机构信息

M.V. Lomonosov Moscow State University, Leninskie gory, 1-3, 119991 Moscow, Russia.

出版信息

Molecules. 2020 Mar 7;25(5):1211. doi: 10.3390/molecules25051211.

DOI:10.3390/molecules25051211
PMID:32156064
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7179467/
Abstract

This review presents the last decade of studies on the synthesis of various types of small-molecule inhibitors of the p53- Mouse double minute 2 homolog (MDM2) protein-protein interaction. The main focus is placed on synthetic approaches to such molecules, their cytotoxicity, and MDM2 binding characteristics.

摘要

本文综述了过去十年中关于合成各种类型的 p53-鼠双微体 2 同源物（MDM2）蛋白-蛋白相互作用小分子抑制剂的研究。本文主要关注这些分子的合成方法、细胞毒性和 MDM2 结合特性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574b/7179467/c17efa217c32/molecules-25-01211-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574b/7179467/e2d8e7a055a0/molecules-25-01211-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574b/7179467/6735f14bd3ae/molecules-25-01211-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574b/7179467/a32aff50d82c/molecules-25-01211-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574b/7179467/dc000e50c07f/molecules-25-01211-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574b/7179467/1aebdbb87d99/molecules-25-01211-sch002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574b/7179467/1a7ef18eb997/molecules-25-01211-sch003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574b/7179467/e961615e2657/molecules-25-01211-sch004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574b/7179467/9947dd2bbc37/molecules-25-01211-sch005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574b/7179467/6eaf3ff76f37/molecules-25-01211-sch006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574b/7179467/a80fe66619a2/molecules-25-01211-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574b/7179467/5ec684199d8a/molecules-25-01211-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574b/7179467/21d571193e92/molecules-25-01211-sch007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574b/7179467/a6b0a8813cd6/molecules-25-01211-sch008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574b/7179467/7882704b143e/molecules-25-01211-sch009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574b/7179467/e8fa57db76bf/molecules-25-01211-sch010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574b/7179467/77cbfa4cf4ec/molecules-25-01211-sch011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574b/7179467/b2bf55717d7a/molecules-25-01211-sch012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574b/7179467/ebdde907f6b4/molecules-25-01211-sch013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574b/7179467/c17efa217c32/molecules-25-01211-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574b/7179467/e2d8e7a055a0/molecules-25-01211-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574b/7179467/6735f14bd3ae/molecules-25-01211-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574b/7179467/a32aff50d82c/molecules-25-01211-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574b/7179467/dc000e50c07f/molecules-25-01211-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574b/7179467/1aebdbb87d99/molecules-25-01211-sch002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574b/7179467/1a7ef18eb997/molecules-25-01211-sch003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574b/7179467/e961615e2657/molecules-25-01211-sch004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574b/7179467/9947dd2bbc37/molecules-25-01211-sch005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574b/7179467/6eaf3ff76f37/molecules-25-01211-sch006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574b/7179467/a80fe66619a2/molecules-25-01211-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574b/7179467/5ec684199d8a/molecules-25-01211-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574b/7179467/21d571193e92/molecules-25-01211-sch007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574b/7179467/a6b0a8813cd6/molecules-25-01211-sch008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574b/7179467/7882704b143e/molecules-25-01211-sch009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574b/7179467/e8fa57db76bf/molecules-25-01211-sch010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574b/7179467/77cbfa4cf4ec/molecules-25-01211-sch011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574b/7179467/b2bf55717d7a/molecules-25-01211-sch012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574b/7179467/ebdde907f6b4/molecules-25-01211-sch013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/574b/7179467/c17efa217c32/molecules-25-01211-g006.jpg

相似文献

1
Recent Small-Molecule Inhibitors of the p53-MDM2 Protein-Protein Interaction.近期的 p53-MDM2 蛋白-蛋白相互作用小分子抑制剂。
Molecules. 2020 Mar 7;25(5):1211. doi: 10.3390/molecules25051211.
2
Targeting MDM2-p53 interaction for cancer therapy: are we there yet?靶向MDM2-p53相互作用用于癌症治疗：我们做到了吗？
Curr Med Chem. 2014;21(5):553-74. doi: 10.2174/09298673113206660325.
3
Natural product MDM2 inhibitors: anticancer activity and mechanisms of action.天然产物 MDM2 抑制剂：抗癌活性及作用机制。
Curr Med Chem. 2012;19(33):5705-25. doi: 10.2174/092986712803988910.
4
Molecular interaction fields and 3D-QSAR studies of p53-MDM2 inhibitors suggest additional features of ligand-target interaction.基于分子相互作用场和 3D-QSAR 的 p53-MDM2 抑制剂研究提示了配体-靶标相互作用的其他特征。
J Chem Inf Model. 2010 Aug 23;50(8):1451-65. doi: 10.1021/ci100113p.
5
Synthesis and biological evaluation of thio-benzodiazepines as novel small molecule inhibitors of the p53-MDM2 protein-protein interaction.硫代苯并二氮杂䓬类化合物的合成与生物评价作为新型小分子 p53-MDM2 蛋白-蛋白相互作用抑制剂。
Eur J Med Chem. 2011 Nov;46(11):5654-61. doi: 10.1016/j.ejmech.2011.09.043. Epub 2011 Oct 2.
6
Targeting the MDM2-p53 protein-protein interaction with prenylchalcones: Synthesis of a small library and evaluation of potential antitumor activity.用类异戊烯基查耳酮靶向 MDM2-p53 蛋白-蛋白相互作用：一个小文库的合成及潜在抗肿瘤活性的评价。
Eur J Med Chem. 2018 Aug 5;156:711-721. doi: 10.1016/j.ejmech.2018.07.037. Epub 2018 Jul 17.
7
Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53-MDM2 Interaction Useful in Targeted Cancer Therapy.螺环-氧吲哚类作为一种有前途的小分子 p53-MDM2 相互作用抑制剂用于靶向癌症治疗。
Top Curr Chem (Cham). 2017 Feb;375(1):3. doi: 10.1007/s41061-016-0089-0. Epub 2016 Dec 9.
8
Small-molecule MDM2-p53 inhibitors: recent advances.小分子MDM2-p53抑制剂：最新进展
Future Med Chem. 2015;7(5):631-45. doi: 10.4155/fmc.15.13.
9
Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.用于癌症治疗临床试验的MDM2-p53蛋白-蛋白相互作用小分子抑制剂（MDM2抑制剂）。
J Med Chem. 2015 Feb 12;58(3):1038-52. doi: 10.1021/jm501092z. Epub 2014 Nov 14.
10
A yeast two-hybrid system for the screening and characterization of small-molecule inhibitors of protein-protein interactions identifies a novel putative Mdm2-binding site in p53.一种用于筛选和鉴定蛋白质-蛋白质相互作用小分子抑制剂的酵母双杂交系统，在 p53 中鉴定出一个新的假定的 Mdm2 结合位点。
BMC Biol. 2017 Nov 9;15(1):108. doi: 10.1186/s12915-017-0446-7.

引用本文的文献

1
Strategies for p53 Activation and Targeted Inhibitors of the p53-Mdm2/MdmX Interaction.p53激活策略及p53-Mdm2/MdmX相互作用的靶向抑制剂
Cells. 2025 Apr 12;14(8):583. doi: 10.3390/cells14080583.
2
Affinity-based protein profiling of MDM2 inhibitor Navtemadlin.基于亲和力的MDM2抑制剂Navtemadlin的蛋白质谱分析。
Chem Sci. 2025 Mar 12;16(16):6886-6894. doi: 10.1039/d5sc00120j. eCollection 2025 Apr 16.
3
Insights into the Interaction Mechanisms of Peptide and Non-Peptide Inhibitors with MDM2 Using Gaussian-Accelerated Molecular Dynamics Simulations and Deep Learning.

本文引用的文献

1
Inhibition of p53 inhibitors: progress, challenges and perspectives.p53 抑制剂的抑制：进展、挑战和展望。
J Mol Cell Biol. 2019 Jul 19;11(7):586-599. doi: 10.1093/jmcb/mjz075.
2
Design of indole- and MCR-based macrocycles as p53-MDM2 antagonists.基于吲哚和多组分反应的大环化合物作为p53-MDM2拮抗剂的设计
Beilstein J Org Chem. 2019 Feb 20;15:513-520. doi: 10.3762/bjoc.15.45. eCollection 2019.
3
Design and synthesis of new substituted spirooxindoles as potential inhibitors of the MDM2-p53 interaction.新型取代螺环氧化吲哚的设计与合成及其作为 MDM2-p53 相互作用抑制剂的潜力。
基于高斯加速分子动力学模拟和深度学习的肽类和非肽类抑制剂与 MDM2 相互作用机制的研究。
Molecules. 2024 Jul 18;29(14):3377. doi: 10.3390/molecules29143377.
4
Unlocking the Gateway: The Spatio-Temporal Dynamics of the p53 Family Driven by the Nuclear Pores and Its Implication for the Therapeutic Approach in Cancer.解锁门户：核孔驱动的 p53 家族的时空动力学及其对癌症治疗方法的启示。
Int J Mol Sci. 2024 Jul 7;25(13):7465. doi: 10.3390/ijms25137465.
5
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future.MDM2 抑制剂在癌症治疗中的应用：过去、现在与未来。
Pharmacol Rev. 2024 May 2;76(3):414-453. doi: 10.1124/pharmrev.123.001026.
6
Activation of p53 signaling and regression of breast and prostate carcinoma cells by spirooxindole-benzimidazole small molecules.螺环氧化吲哚-苯并咪唑小分子激活p53信号通路并促使乳腺癌和前列腺癌细胞消退。
Front Pharmacol. 2024 Apr 8;15:1358089. doi: 10.3389/fphar.2024.1358089. eCollection 2024.
7
Diastereoselective Synthesis of Dispiro[Imidazothiazolotriazine-Pyrrolidin-Oxindoles] and Their Isomerization Pathways in Basic Medium.在碱性介质中，非对映选择性合成双螺[咪唑并噻唑并吡咯并吲哚]及其异构化途径。
Int J Mol Sci. 2023 Nov 15;24(22):16359. doi: 10.3390/ijms242216359.
8
Reinvestigation of Passerini and Ugi scaffolds as multistep apoptotic inducers dual modulation of caspase 3/7 and P53-MDM2 signaling for halting breast cancer.重新研究Passerini和Ugi支架作为多步凋亡诱导剂：对caspase 3/7和P53-MDM2信号进行双重调节以阻止乳腺癌
RSC Adv. 2023 Sep 20;13(40):27722-27737. doi: 10.1039/d3ra04029a. eCollection 2023 Sep 18.
9
Emerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer.新兴的癌症治疗策略：克服不可成药蛋白。
Int J Biol Sci. 2023 Jun 26;19(11):3360-3382. doi: 10.7150/ijbs.83026. eCollection 2023.
10
Optimized spirooxindole-pyrazole hybrids targeting the p53-MDM2 interplay induce apoptosis and synergize with doxorubicin in A549 cells.针对 p53-MDM2 相互作用的优化螺环氧化吲哚-吡唑杂合体诱导细胞凋亡，并与阿霉素在 A549 细胞中协同作用。
Sci Rep. 2023 May 8;13(1):7441. doi: 10.1038/s41598-023-31209-3.
Bioorg Chem. 2019 May;86:598-608. doi: 10.1016/j.bioorg.2019.01.053. Epub 2019 Jan 31.
4
Synthesis of new thiazolo-pyrrolidine-(spirooxindole) tethered to 3-acylindole as anticancer agents.合成新型噻唑并吡咯烷-(螺吲哚)连接 3-乙酰基吲哚作为抗癌剂。
Bioorg Chem. 2019 Feb;82:423-430. doi: 10.1016/j.bioorg.2018.10.036. Epub 2018 Oct 23.
5
p53-Mdm2 Interaction Inhibitors as Novel Nongenotoxic Anticancer Agents.p53-Mdm2 相互作用抑制剂作为新型非遗传毒性抗癌药物。
Curr Cancer Drug Targets. 2018;18(8):749-772. doi: 10.2174/1568009617666170623111953.
6
Discovery of Novel Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one Compounds as Chemically Stable and Orally Active Inhibitors of the MDM2-p53 Interaction.新型螺[3H-吲哚-3,2'-吡咯烷]-2(1H)-酮化合物作为MDM2-p53相互作用的化学稳定且口服活性抑制剂的发现
J Med Chem. 2016 Nov 23;59(22):10147-10162. doi: 10.1021/acs.jmedchem.6b00900. Epub 2016 Nov 15.
7
Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 Inhibitors.新型3,3-二取代哌啶类化合物作为口服生物可利用、强效且有效的HDM2-p53抑制剂的发现。
ACS Med Chem Lett. 2016 Jan 20;7(3):324-9. doi: 10.1021/acsmedchemlett.5b00472. eCollection 2016 Mar 10.
8
How To Design a Successful p53-MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures.如何设计一种成功的p53-MDM2/X相互作用抑制剂：基于晶体结构的全面概述
ChemMedChem. 2016 Apr 19;11(8):757-72. doi: 10.1002/cmdc.201500487. Epub 2015 Dec 16.
9
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.二氢异喹啉酮衍生物（NVP-CGM097）的发现：一种高效且选择性的MDM2抑制剂，正在p53野生型肿瘤中进行1期临床试验。
J Med Chem. 2015 Aug 27;58(16):6348-58. doi: 10.1021/acs.jmedchem.5b00810. Epub 2015 Aug 5.
10
Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with a distinct binding mode.发现二氢异喹啉酮衍生物作为p53-MDM2相互作用的新型抑制剂，具有独特的结合模式。
Bioorg Med Chem Lett. 2015 Sep 1;25(17):3621-5. doi: 10.1016/j.bmcl.2015.06.058. Epub 2015 Jun 23.